Regulatory News:
Karo Bio AB (publ)(STO:KARO) today announced that Chief Financial
Officer, Erika Söderberg Johnson, leaves her position.
Karo Bio’s CFO Erika Söderberg Johnson will leave Karo Bio at the end of
the year. She has been CFO at Karo Bio since 2007. The search for a new
CFO has been initiated.
About Karo Bio
Karo Bio is a pharmaceutical company focused on the research and
development of innovative drugs for large medical needs. The company
runs a number of drug development projects within the indication areas
cardiovascular and metabolic diseases, neuropsychiatry, inflammation,
autoimmune diseases, cancer and women’s health. An important foundation
for the company’s activities is its unique knowledge of nuclear
receptors as target proteins for the development of novel
pharmaceuticals, as well as related mechanisms of action. Karo Bio is
based in Huddinge, Sweden, has around 70 employees and is listed on
NASDAQ OMX Stockholm.
This information is such that Karo Bio is required to disclose under the
Swedish Securities Market Act. The information was disclosed on
September 30, 2011, 13:00 CET.
This press release is also available online at www.karobio.se
and www.newsroom.cision.com
This information was brought to you by Cision http://www.cisionwire.com
